Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 3/20 | 0.54 |
| ▸ | CA2 | P00918 | 3/20 | 0.54 |
| ▸ | CA4 | P22748 | 3/20 | 0.54 |
| ▸ | CA6 | P23280 | 3/20 | 0.54 |
| ▸ | CA5A | P35218 | 3/20 | 0.54 |
| ▸ | CA7 | P43166 | 3/20 | 0.54 |
| ▸ | CA9 | Q16790 | 3/20 | 0.54 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.54 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.54 |
| ▸ | F13A1 | P00488 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | THPO | P40225 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | CA3 | P07451 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | MTOR | P42345 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4561516 | 0.98 | PAOX (0.58) | PAOXCA12CA2CA4CA6 | |
| SCHEMBL4562729 | 0.98 | PAOX (0.58) | PAOXCA12CA2CA4CA6 | |
| SCHEMBL322792 | 0.96 | ALOX15 (0.54) | PAOXCA12CA2CA4CA6 | |
| SCHEMBL427900 | 0.96 | TDP1 (0.59) | PAOXCA12CA2CA4CA6 | |
| Hydrochloric Acid SCHEMBL28341342 | 0.94 | UBE2N (0.58) | PAOXCA12CA2CA4CA6 | |
| Hydrochloric Acid SCHEMBL6114403 | 0.94 | UBE2N (0.58) | PAOXCA12CA2CA4CA6 | |
| SCHEMBL322920 | 0.94 | PAOX (0.53) | PAOXCA12CA2CA4CA6 | |
| SCHEMBL322999 | 0.94 | PAOX (0.53) | PAOXCA12CA2CA4CA6 | |
| SCHEMBL323710 | 0.93 | TDP1 (0.61) | PAOXCA12CA2CA4CA6 | |
| SCHEMBL7522951 | 0.91 | ALOX15 (0.56) | PAOXCA12CA2CA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020045780-A1 | Biologically active spermidine analogues, pharmaceutical compositions and methods of treatment | BERGERON RAYMOND J (US) | 2002-04-18 | — | — | US | claimed |
| US-6235794-B1 | ANTICANCER AGENT | UNIVERSITY OF FLORIDA | 2001-05-22 | — | — | US | claimed |
| WO-2025021106-A1 | PYRIDIN[3,2-D]PYRIMIDIN-2-AMINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND USE THEREOF | 北京森妙生物科技有限公司 | 2025-01-30 | — | — | WO | disclosed |
| CN-111971070-A | HSP90-targeting conjugates and formulations thereof | 塔弗达治疗有限公司 | 2020-11-20 | — | — | CN | disclosed |
| CN-111601616-A | Compositions and methods for depleting CD117+ cells | 美真达治疗公司 | 2020-08-28 | — | — | CN | disclosed |
| CN-111465612-A | B cell maturation antigen binding proteins | 哈普恩治疗公司 | 2020-07-28 | — | — | CN | disclosed |
| WO-2009148659-A2 | ANTIMALARIAL QUINOLINES AND METHODS OF USE THEREOF | GEORGETOWN UNIVERSITY (US) | 2009-12-10 | — | — | WO | disclosed |
| US-7056926-B2 | Platelet ADP receptor inhibitors | PORTOLA PHARMACEUTICALS INC. (US) | 2006-06-06 | — | — | US | disclosed |
| US-20020045780-A1 | Biologically active spermidine analogues, pharmaceutical compositions and methods of treatment | BERGERON RAYMOND J (US) | 2002-04-18 | — | — | US | disclosed |
| US-20020045780-A1 | Biologically active spermidine analogues, pharmaceutical compositions and methods of treatment | BERGERON RAYMOND J (US) | 2002-04-18 | — | — | US | disclosed |
| US-6235794-B1 | ANTICANCER AGENT | UNIVERSITY OF FLORIDA | 2001-05-22 | — | — | US | disclosed |
| US-6235794-B1 | ANTICANCER AGENT | UNIVERSITY OF FLORIDA | 2001-05-22 | — | — | US | disclosed |
| EP-0353752-A1 | N-2, 3-butadienyl triaminoalkane derivatives | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-02-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020045780-A1 | Biologically active spermidine analogues, pharmaceutical compositions and methods of treatment | SRM, SLC7A1, CATSPER1 | PAOX 1458/4885CA12 3973/4885CA2 984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.